Clinical Trial Update: Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 clinical trial testing pembrolizumab combined with ADG106 for advanced solid tumors and triple-negative breast cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors
• Triple-negative Breast Cancer

Drugs mentioned

• ADG106
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: National University Hospital, Singapore | Conditions: Advanced Solid Tumor, Triple Negative Breast Cancer | Phase 1, Phase 2 | Status: RECRUITING